RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Saxagliptin and Alogliptin Noninferior for CV Ischemic Events in Patients at High Risk with T2DM and Coronary Disease
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 15
SP 17
OP 23
DO 10.1177/155989771315012
UL http://mdc.sagepub.com/content/13/15/17.abstract
AB Antihyperglycemic therapies have been shown to reduce microvascular events; however, their impact on macrovascular events has not been well established. Saxagliptin and alogliptin, both selective dipeptidyl peptidase 4 (DPP-4) inhibitors, are incretin-based antihyperglycemic therapies that improve glycemic control in type 2 diabetes mellitus (T2DM). This article discusses the purpose of the SAVOR-TIMI 53 and EXAMINE trials was to determine if treatment with saxagliptin or alogliptin, respectively, would be noninferior to placebo for major adverse cardiac events in patients with T2DM at heightened risk of CV events [Scirica BM et al. Am Heart J 2011; White WB et al. N Engl J Med 2013].